What are your top takeaways from ASTRO 2022?

1. NRG RTOG 1005: A Phase III Trial of Hypofractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation Plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer

The results showed that with hypofractionation and SIB technique, 7 year...

1. RTOG 1005 - In a large phase 3 trial, demonstrated the safety and efficacy of simultaneous integrated boost in the management of early stage practice. The question that emerges is who to offer this approach to.

2. Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multicenter Analysis ...

1. NRG/RTOG 1112: It is a phase III study of sorafenib vs. SBRT followed by sorafenib in locally advanced HCC. This study showed the addition of SBRT improved overall survival (OS), progression-free survival (PFS), Time to progression (TTP) without increased toxicity in this patient population. This...

1. NRG/RTOG-1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma. The results of this long-awaited trial led by Dr. @Dr. First Last showed the benefit of adding SBRT to sorafenib in patients with locally advanced hepa...

There were many interesting things presented at ASTRO this year. I have chosen the most important abstract for our near-term practice in treating breast cancer patients and two others that are quite novel but which will need much more study before considering whether to adopt them.

1. Abstract 1: Vi...

The issue of using IMPT vs. IMRT in HNC is contentious, with retrospective data suggesting likely similar tumor control but conflicting data regarding the potential clinical superiority of IMPT in reducing acute and late sequellae. While some publications suggest DVH-based superiority of IMPT regard...

Good presentations